The company reported $1.9 million in Q1 revenues amid a widened net loss of $7.9 million that was driven by increased operating expenses.
The two Netherlands-based firms will market their joint offering to pharmaceutical companies and others researching immune system-related diseases.
Genetic material found in tooth samples from the Bronze Age, Iron Age, and Medieval period points to migrations from Siberia at the Bronze Age-Iron Age transition.
Two new studies of stage I to III CRC suggest that the presence of ctDNA in the months after surgery or chemotherapy can help identify patients who go on to relapse.
The company reaffirmed its full fiscal year 2019 comparable, currency-neutral revenue guidance, and updated its adjusted diluted EPS guidance.
NanoCellect's Wolf Cell Sorter and N1 single-cell plate dispenser uses lasers and piezoelectricity to gently sort cells for downstream applications.
The Bayesian Estimation of Variants in Regions tool estimates regional heritability using summary statistics from genome-wide association studies.
The company will offer 3.75 million shares of its common stock at $21 per share.
Bio-Rad also disclosed during an earnings call that it acquired an undisclosed company that will expand its genomic reagents product portfolio.
Flu test sales were the second-highest for a quarter in the firm's history but were still $17.4 million lower than the year-ago quarter due to a much less intense flu season.
The company saw $1.0 million in revenues for the quarter, including $976,000 from commercial testing, and attributed the growth to its pathology partnership initiative.
The company reported $26 million in total revenues for the quarter and said that testing services revenues more than doubled year over year.
To solve the problem, the researchers developed new variants of the editors that still edit DNA efficiently but have significantly lower RNA editing activity.
The La Jolla, California-based firm plans to use the funds to accelerate research partnerships around its LunaDNA genomic data sharing platform.
The revenue increase was driven by a jump in sales of products including the company's flagship Epi proColon blood-based colorectal cancer screening test.
The company reported double-digit year-over-year growth in the number of billable genetic tests it delivered during the first quarter of 2019.
For the three months ended March 31, the firm generated $40.6 million in revenues, missing the consensus Wall Street estimate of $47.2 million.
The firm reported total revenues of $216.6 million in Q3 2019 compared to $183.1 million a year ago, but it fell short of the consensus Wall Street estimate was $217.5 million.
The company's total revenue for the three months ended March 31 was $108.8 million compared to $92.6 million in the first quarter of 2018, exceeding analyst expectations.
Researchers built a single-cell gene expression atlas of premalignant lesions and early gastric cancer to find shifts that could portend disease progression.
Investigators used gene panel sequence data to look at rare de novo variant frequencies in potential risk genes for neurodevelopmental disorders with epilepsy.
Eurofins Scientific will help Adial validate a companion diagnostic for a drug being developed and identify patients for enrollment into a Phase III trial.
The company will use the proceeds to expand its R&D capabilities and its commercial operations.
Qiagen also announced plans to launch a new $100 million share repurchase program after completing its current $200 million share repurchase commitment.
The firm said that it placed about 50 sample-to-answer molecular systems under contract during Q1, and it had about 625 active sample-to-answer product customers.
University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.
A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.
Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.
In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.